Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Eric Jonasch MD Advisory Board

Elizabeth Smyth MD Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · December 10, 2018

Management of Brain Metastases in the Era of Checkpoint Inhibitors

Interview by

Aman Shah MD

Interview with

Manmeet Ahluwalia MD, FACP, MBA

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

featured

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation for Leptomeningeal Disease

Commentary · December 08, 2022
featured

2022 Top Story in Brain Cancer: GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

Commentary · December 06, 2022
featured

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

Commentary · December 06, 2022
story of the week

Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

JAMA Oncol · December 05, 2022

updated
story of the week

Efficacy and Safety of Trametinib With or Without Dabrafenib for Pediatric BRAF V600–Mutant Low-Grade Glioma

J. Clin. Oncol · December 05, 2022
featured

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019

Neuro-oncology · November 29, 2022
story of the week

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

JAMA Oncol · November 22, 2022

updated
featured

Palliative and End-of-Life Care in Adults With Malignant Brain Tumors

Neuro-oncology · November 16, 2022
story of the week

Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

J. Clin. Oncol · November 15, 2022

updated
story of the week

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

J. Clin. Oncol · November 14, 2022

Brain Cancer

Management of Brain Metastases in the Era of Checkpoint Inhibitors

Brain Cancer Center of Excellence

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation for Leptomeningeal Disease

2022 Top Story in Brain Cancer: GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas

2022 Top Story in Brain Cancer: Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

Autologous Tumor Lysate–Loaded Dendritic Cell Vaccination Extends Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Efficacy and Safety of Trametinib With or Without Dabrafenib for Pediatric BRAF V600–Mutant Low-Grade Glioma

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

Palliative and End-of-Life Care in Adults With Malignant Brain Tumors

Efficacy of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone for Treatment of Recurrent Glioblastoma

Further Reading

Clinical Outcomes in Patients With T4 and/or N2 Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

Valemetostat Monotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma

Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphoma

Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer

Efficacy of Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Ponsegromab for Treating Cancer Cachexia

Related Videos